Results 51 to 60 of about 48,364 (325)

Cost-Utility Analysis of Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip and Total Knee Replacement Surgeries in the English National Health Service [PDF]

open access: yes, 2018
Background: Major orthopedic surgery, such as elective total hip replacement (eTHR) and elective total knee replacement (eTKR), are associated with a higher risk of venous thromboembolism (VTE) than other surgical procedures.
Anderson   +53 more
core   +4 more sources

Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting

open access: yesJournal of Personalized Medicine, 2022
Apixaban and rivaroxaban are the two most prescribed direct factor Xa inhibitors. With the increased use of DOACs in real-world settings, safety and efficacy concerns have emerged, particularly regarding their concomitant use with other drugs. Increasing
Camille Lenoir   +9 more
semanticscholar   +1 more source

Does amiodarone impact on apixaban levels? The effect of amiodarone on apixaban level among Thai patients with non-valvular Atrial Fibrillation.

open access: yesPLoS ONE
BackgroundApixaban and amiodarone are drugs used for non-valvular atrial fibrillation (NVAF) in routine practice. The evidence about apixaban plasma levels in patients who receive apixaban with amiodarone, including bleeding outcomes, has been limited ...
Sutee Limcharoen   +7 more
doaj   +1 more source

Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation [PDF]

open access: yes, 2016
This is an Accepted Manuscript of an article published by Taylor & Francis GroupNon-vitamin K antagonist oral anticoagulants (NOACs) reduce the risk of thromboembolism in patients with atrial fibrillation (AF).
Artman, Benjamin   +8 more
core   +2 more sources

Quick reference guide to apixaban

open access: yesVascular Health and Risk Management, 2017
Direct oral anticoagulants (DOACs) are being increasingly used in the clinical setting for patients at risk of venous thromboembolism (VTE) and/or stroke. These medications offer valued benefits for long-term use, including a fast onset of anticoagulation, fixed anticoagulation profile (and consequent prescription of specified doses) and no requirement
Hurst, K, O'Callaghan, J, Handa, A
openaire   +6 more sources

Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial.

open access: yesJournal of the American Medical Association (JAMA)
Importance Atrial cardiopathy is associated with stroke in the absence of clinically apparent atrial fibrillation. It is unknown whether anticoagulation, which has proven benefit in atrial fibrillation, prevents stroke in patients with atrial cardiopathy
Hooman Kamel   +499 more
semanticscholar   +1 more source

Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end‐stage kidney disease: A national cohort study

open access: yesJournal of Hospital Medicine, 2022
Background Patients with end‐stage kidney disease (ESKD) are at significantly increased risk for both thrombosis and bleeding relative to those with normal renal function.
M. Ellenbogen   +5 more
semanticscholar   +1 more source

Budget impact analysis of apixaban to treat and prevent venous thromboembolism in Italy

open access: yesFarmeconomia: Health Economics and Therapeutic Pathways, 2016
BACKGROUND: Venous thromboembolism (VTE), a collective term for deep vein thrombosis (DVT) and pulmonary embolism (PE), is a serious vascular condition associated to high economic and clinical burden. Apixaban, a Novel Oral Anticoagulant (NOAC) has shown
Marco Bellone   +2 more
doaj   +1 more source

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. [PDF]

open access: yes, 2015
Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant morbidity and mortality from cardioembolic complications like stroke.
Acharya, Tushar, Deedwania, Prakash
core   +1 more source

Head-to-head Efficacy and Safety of Rivaroxaban, Apixaban and Dabigatran in an Observational Nationwide Targeted Trial.

open access: yesEuropean Heart Journal - Cardiovascular Pharmacotherapy, 2022
AIMS The advantages of direct oral anticoagulants (DOACs) over warfarin are well established in atrial fibrillation (AF) patients, however, studies that can guide in the selection between different DOACs are limited.
Y. Talmor-Barkan   +6 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy